Back to Results
First PageMeta Content
Carbamates / Organofluorides / Gilead Sciences / Non-nucleoside reverse transcriptase inhibitors / Darunavir / Tenofovir/emtricitabine / Atazanavir / Antiretroviral drug / Tenofovir / Chemistry / Organic chemistry / Protease inhibitors


Clinical Commissioning Policy: Use of cobicistat (Tybost®) as a booster in treatment of HIV positive adults and adolescents 1
Add to Reading List

Document Date: 2015-03-23 14:05:46

Open Document

File Size: 277,08 KB

Share Result on Facebook

City

Sorrento / /

Company

ACS / Policy Statement NHS England / Gilead Sciences Ltd. / Immune Deficiency Syndromes / NHS England Clinical Reference Group / /

Country

United Kingdom / Italy / /

Currency

pence / /

IndustryTerm

HIV treatment / HIV care / HIV Therapy / healthcare / treatment of HIV / medicinal products / /

MedicalCondition

HIV / Infectious Disease / HIV RNA / /

MedicalTreatment

alternative therapies / Antiretroviral therapy / /

Organization

NHS / /

Position

Major / forward / /

Product

Efavirenz / tenofovir disoproxil fumarate / abacavir / lamivudine / nevirapine / /

PublishedMedium

Journal of Acquired Immune Deficiency Syndromes / /

Technology

pharmacokinetics / pharmacodynamics / /

SocialTag